Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 9,379	$ 8,896
General and administrative	3,408	3,482
Total operating expenses	12,787	12,378
Loss from operations	(12,787)	(12,378)
Total other income (expense), net	835	224
Consolidated net loss	(11,952)	(12,154)
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	1	1
Net loss attributable to aTyr Pharma, Inc.	$ (11,951)	$ (12,153)
Net loss per share - basic	$ (0.29)	$ (0.44)
Net loss per share - diluted	$ (0.29)	$ (0.44)
Shares used in computing net loss per share, basic	41,897,706	27,818,379
Shares used in computing net loss per share, diluted	41,897,706	27,818,379